ResearchMoz

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

GBI Research
Published Date » 2014-02-06
No. Of Pages » N/A

GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

Scope

  • An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment
  • Analysis of the major systemic therapies in the current psoriasis marketed landscape
  • Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
  • Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
  • Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication

Reasons to Buy

  • Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
  • Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted
  • Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages
  • Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 5

2 Executive Summary 6
2.1 Changes to Treatment Usage Patterns will Drive Market Growth 6
2.2 Biologics to Gain Prominence as Promising Novel Drugs Enter the Market 6

3 Introduction 7
3.1 Overview 7
3.2 Epidemiology 8
3.3 Etiology, Co-morbidities and Risk Factors 9
3.3.1 Genetics 9
3.3.2 Psoriatic Arthritis 9
3.3.3 Mental Health Disorders 10
3.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 10
3.3.5 Infections 10
3.3.6 Köebner Phenomenon 11
3.3.7 Other Immune-mediated Diseases 11
3.4 Pathophysiology 11
3.5 Diagnosis 12
3.6 Treatment Options 12
3.6.1 Pharmacological Therapies 13
3.6.2 Non-pharmacological Therapies 14
3.6.3 Combination and Rotational Therapies 14
3.6.4 Quality of Life Assessments 15
3.7 Summary 15
3.8 GBI Research Report Guidance 15

4 Marketed Products 16
4.1 Overview 16
4.2 Methotrexate-based Products 16
4.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) – Novartis 17
4.4 Soriatane (acitretin) – Steifel Laboratories 18
4.5 Fumaderm (dimethyl fumarate and ethyl fumarate) – Biogen Idec 19
4.6 Humira (adalimumab) – Abbvie Inc. 20
4.7 Enbrel (etanercept) – Amgen Inc. 21
4.8 Remicade (infliximab) – Janssen Biotech 22
4.9 Stelara (ustekinumab) – Janssen Biotech 23
4.10 Marketed Products Heat Map 24

5 Pipeline 27
5.1 Overview 27
5.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type 28
5.3 Pipeline Distribution by Molecular Target 30
5.4 Clinical Trial Landscape 32
5.4.1 Clinical Trial Duration 32
5.4.2 Clinical Trial Size 36
5.5 Clinical trial failure rates 40
5.6 Primary and Secondary Endpoints 41
5.7 Summary of Psoriasis Clinical Trials 43
5.8 Promising pipeline molecules 43
5.8.1 Ixekizumab – Eli Lilly 43
5.8.2 Xeljanz (tofacitinib) – Pfizer 44
5.8.3 Brodalumab – Amgen 45
5.8.4 Apremilast – Celgene 46
5.8.5 Secukinumab – Alcon 47
5.9 Heat Map for Pipeline Products 47

6 Market Forecast to 2020 52
6.1 Overview 52
6.2 Global Market 52
6.3 North America 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Treatment 56
6.3.3 Market Size 58
6.4 Top Five EU Markets 59
6.4.1 Treatment Usage Patterns 59
6.4.2 Annual Cost of Treatment 60
6.4.3 Market Size 61
6.5 Japan 62
6.5.1 Treatment Usage Patterns 62
6.5.2 Annual Cost of Treatment 63
6.5.3 Market Size 64
6.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market 65
6.6.1 Drivers 65
6.6.2 Barriers 65

7 Co-development and Licensing deals 67
7.1 Co-development Deals 67
7.1.1 Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab 70
7.1.2 Lycera Enters into Research Agreement with Merck & Co. 70
7.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 70
7.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 70
7.2 Licensing Deals 72
7.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 75
7.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy's Labs 75
7.2.3 Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 75
7.2.4 Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 75

8 Appendix 76
8.1 All Pipeline Drugs by Phase 76
8.1.1 Discovery 76
8.1.2 Preclinical 78
8.1.3 Phase I 82
8.1.4 Phase II 84
8.1.5 Phase III 86
8.1.6 Undisclosed 87
8.2 Market Forecasts to 2020 87
8.2.1 Major Developed Markets 87
8.2.2 US 88
8.2.3 UK 88
8.2.4 France 89
8.2.5 Germany 89
8.2.6 Italy 90
8.2.7 Spain 90
8.2.8 Japan 91
8.2.9 Canada 91
8.3 Abbreviations 92
8.4 References 93
8.5 References for Heat Maps 98
8.5.1 Marketed Products 98
8.5.2 Pipeline products 98
8.6 Methodology 100
8.6.1 Secondary Research 100
8.6.2 Therapeutic Landscape 100
8.7 Contact Us 100
8.8 Disclaimer 101

List of Tables


Table 1: Type of Psoriasis 8
Table 2: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Discovery, 2014 76
Table 3: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Preclinical/IND/CTA-filed, 2014 78
Table 4: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase I, 2014 82
Table 5: Systemic Psoriasis Therapeutics Market, Global, Phase II, Discovery, 2014 84
Table 6: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase III/Pre-registration, 2014 86
Table 7: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Undisclosed, 2014 87
Table 8: Systemic Psoriasis Market Forecast, Global, 2013–2020 87
Table 9: Systemic Psoriasis Market Forecast, US, 2013–2020 88
Table 10: Systemic Psoriasis Market Forecast, UK, 2013–2020 88
Table 11: Systemic Psoriasis Market Forecast, France, 2013–2020 89
Table 12: Systemic Psoriasis Market Forecast, Germany, 2013–2020 89
Table 13: Systemic Psoriasis Market Forecast, Italy, 2013–2020 90
Table 14: Systemic Psoriasis Market Forecast, Spain, 2013–2020 90
Table 15: Systemic Psoriasis Market Forecast, Japan, 2013–2020 91
Table 16: Systemic Psoriasis Market Forecast, Canada, 2013–2020 91
Table 17: Breakdown of ‘Others’ Category 99
Table 18: Breakdown of ‘Combination’ Category 99

List of Figures


Figure 1: Systemic Psoriasis Therapeutics Market, Global, Market Size, 2013–2020 6
Figure 2: Psoriasis Treatment Algorithms 13
Figure 3: Heat Map for Marketed Products 24
Figure 4: Heat Map for Marketed Products (continued) 25
Figure 5: Psoriasis Therapeutics Market, Global, Pipeline, 2013 28
Figure 6: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 30
Figure 7: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 31
Figure 8: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type, (months) 2006–2012 33
Figure 9: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecular Target, (months) 2006–2012 35
Figure 10: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecule Type, (participants) 2006–2012 37
Figure 11: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecular Target, (participants), 2006–2012 39
Figure 12: Psoriasis Therapeutics Market, Global, Clinical Trial Failure Rate, (%), 2006–2013 40
Figure 13: Psoriasis Therapeutics Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, (%), 2006–2012 41
Figure 14: Psoriasis Therapeutics Market, Global, Frequency of Secondary Endpoints Measured in Clinical Trials, (%), 2006–2012 42
Figure 15: Heat Map for Pipeline Products 48
Figure 16:Heat Map for Marketed Products 49
Figure 17:Heat Map for Marketed Products (continued) 50
Figure 18: Systemic Psoriasis Therapeutics Market, Global, Treatment Patterns (million), 2013–2020 52
Figure 19: Systemic Psoriasis Therapeutics Market, Global, Market Size ($bn), 2013–2020 54
Figure 20: Systemic Psoriasis Therapeutics Market, North America, Treatment Patterns, 2013–2020 55
Figure 21: Systemic Psoriasis Therapeutics Market, North America, Annual Cost of Treatment ($), 2013–2020 56
Figure 22: Systemic Psoriasis Therapeutics Market, North America, Market Size, 2013–2020 58
Figure 23: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020 59
Figure 24: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020 60
Figure 25: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013–2020 61
Figure 26: Systemic Psoriasis Therapeutics Market, Japan, Treatment Patterns (‘000), 2013–2020 62
Figure 27: Systemic Psoriasis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2013–2020 63
Figure 28: Systemic Psoriasis Therapeutics Market, Japan, Market Size ($m), 2013–2020 64
Figure 29: Psoriasis Therapeutics Market, Global, Co-development Deals, 2006–2013 67
Figure 30: Psoriasis Therapeutics Market, Global, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006–2013 69
Figure 31: Psoriasis Therapeutics Market, Global, Licensing Deals, 2006–2013 72
Figure 32: Psoriasis Therapeutics Market, Licensing Deals by Phase, Molecule Type and Aggregate Deal Value ($m), 2006–2013 73

Upcoming Reports:

Pressure Relief Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Pressure relief devices mould around the patients’ body to distribute their weight or relieve pressure over bony areas and are majorly used in patients that are at risk of developing pressure ulcers or pressure issues in middle ear. Some of the highly advanced pressure relief devices are designed such that they remove pressure from different areas of the body at regular intervals. Various pressure-relieving devices are currently available in the market which are placed on top of a mattress and aim at pressure redistribution. These devices are made up of different material and differ...
Orthopedic Biomaterials Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Orthopedic biomaterials are organic or synthetic materials of biologic composition used for internal fixation of fracture. Biomaterial devices which are manufactured for large number of orthopedic applications are commonly termed as ‘Implants’. These biomaterials help in re-establishing the structural integrity of the damaged bone due to trauma or diseased conditions. Biocompatibility of the material is the primary factor to be considered before its usage in orthopedic applications. Other characteristics on which the success of biomaterials in biological applications...
Factor Assays Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Factor assays are mainly undertaken during prolongation of the Activated Partial Thromboplastin Time (APTT) and Partial Thromboplastin Time (PTT) resulting in the deficiency of one or more clotting proteins. Overall a basic general principle is followed by all functional clotting factor assays that involves specific plotting/clotting time from either PTT or APTT depending on which factor it’s being assayed against sample dilution. A quantitative assay of an individual clotting factor is essential to identify inherited deficiency and to monitor replacement therapy and sometimes helps...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014  
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies.  Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...